Pharmacological approaches to the management of schizophrenia: 10 years on

Australasian Psychiatry

Volumn 21, Issue 4, 2013, Pages 329-334

  Castle, David ^a   Keks, Nicholas ^b   Newton, Richard ^a,b   Schweitzer, Isaac ^a   Copolov, David ^a,b   Paoletti, Nick ^a   Burrows, Graham ^a   Tiller, John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Atypical antipsychotic; Hyperprolactinaemia; Metabolic syndrome; Schizophrenia; Typical antipsychotic

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DROPERIDOL; HALOPERIDOL; METABOTROPIC RECEPTOR AGONIST; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

ADD ON THERAPY; AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BREAST CANCER; CARDIOMYOPATHY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSOMNIA; LETHARGY; MAJOR DEPRESSION; MENSTRUAL IRREGULARITY; META ANALYSIS (TOPIC); METABOLIC DISORDER; MYOCARDITIS; NEGATIVE SYNDROME; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; POSITIVE SYNDROME; PSYCHOSIS; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; TREATMENT RESPONSE; WEIGHT GAIN;

ATYPICAL ANTIPSYCHOTIC; HYPERPROLACTINAEMIA; METABOLIC SYNDROME; SCHIZOPHRENIA; TYPICAL ANTIPSYCHOTIC;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERPROLACTINEMIA; METABOLIC SYNDROME X; SCHIZOPHRENIA;

EID: 84889048453     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856213486211     Document Type: Article

References (45)

1. Lambert TJR and Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Austr 2003; 178: S57-61.
2. Welge JA and Keck PE. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacol 2003; 166: 1-10.
3. McGorry P. At issue: Cochrane, early intervention, and mental health reform: analysis, paralysis, or evidence-informed progress? Schizophrenia Bull 2012; 38: 221-224.
4. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-163.
5. Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bull 2010; 38: 167-177.
6. Crossley NA, Constante M, McGuire P, et al. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Brit J Psychiatry 2010; 196: 434-439.
7. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.Molec Psychiatry 2013; 18: 53-66.
8. Leucht S, Heres J, Harmann J, et al. Methodological issues in current antipsychotic drug trials. Schizophrenia Bull 2008; 34: 275-285.
9. Leucht S, Kissling W and Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 1591-1602.
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Eng J Psychiat 2005; 353: 1209-1223.
11. Bick P, Knoesen N and Castle DJ. Clinical implications of the CATIE trials for schizophrenia. Australas Psychiat 2007; 15: 465-469.
12. Jones PB, Barnes TR, Davies L, et al. Randomised controlled trial of the effect of quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiat 2006; 63: 1079-1087.
13. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-1097.
14. Lewis S. Second-generation antipsychotics: a therapeutic downturn? Psychol Med 2009; 39: 1603-1606.
15. Sachdev PS. The current status of tardive dyskinesia. Austr NZ J Psychiat 2000; 34: 355-369.
16. Stahl S. Essential psychopharmacology. 3rd ed. New York: Cambridge University Press, 2012.
17. Bazire S. Psychotropic drug directory 2012. Warwickshire, UK: Lloyd Reinhold, 2012.
18. Castle D, Copolov D, Wykes T, Mueser K, eds. Pharmacological and psychosocial treatments in schizophrenia. 3rd ed. London: Informa Healthcare, 2012.
19. Psychotropic Expert Group. Therapeutic guidelines: psychotropic version 6. Melbourne: Therapeutic Guidelines Limited, 2008.
20. Newton R, Hustig H, Lakshmana R, et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr Med Res Op 2012; 28: 559-567.
21. Morgan V, Waterreus A, Jablensky A, et al. People living with psychotic illness in 2010: the second Australian national survey of psychosis. Austr NZ J Psychiat 2012; 46: 735-752.
22. Galletly C, Foley D, Waterreus A, et al. Cardiometabolic risk factors in people with psychosis: the second Australian national survey of psychosis. Austr NZ J Psychiat 2012; 46: 753-761.
23. Cooper J, Mancuso S, Borland R, et al. Tobacco smoking among people with a psychotic illness: the second Australian national survey of psychosis. Austr NZ J Psychiat 2012; 46: 851-863.
24. Yood MU, DeLorenze G, Quesenberry CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Safety 2009; 18: 791-799.
25. Baker A, Richmond R, Castle D, et al. Coronary heart disease risk reduction intervention among overweight smokers with a psychotic disorder: a pilot trial. Austr NZ J Psychiat 2009; 43: 129-135.
26. Wu R-R, Jin H, Keming G, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomised, placebo-controlled study. Am J Psychiatry 2012; 169: 813-821.
27. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
28. Inder W and Castle D. Antipsychotic-induced hyperprolactinaemia. Austr NZ J Psychiat 2011; 45: 830-837.
29. Zink M, Englisch S and Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Op Psychiatry 2010; 23: 103-111.
30. Taylor DM and Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatrica Scand 2009: 119: 419-425.
31. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162: 130-136.
32. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 720-731.
33. Fleischacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 12: 1115-1125.
34. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiat 2008; 41: 24-28.
35. Van Sant S and Buckley P. Pharmacotherapy for treatment-refractory schizophrenia. Expert Op Pharmacother 2011; 12: 411-434.
36. Tiihonen J, Wahlbeck K and Kivineime V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109: 10-14.
37. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bull 2009; 35: 443-457.
38. Buckley P, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities in schizophrenia. Schizophrenia Bull 2009; 35: 383-402.
39. Bosanac P and Castle D. Schizophrenia and depression. Med J Austr 2012; 4: S36-39.
40. Marsman A, Van den Heuvel MP, Klomp DWJ, et al. Glutamate in schizophrenia: a focussed review and meta-analysis of [1]H-MRS studies. Schizophrenia Bull 20113; 39: 120-129.
41. Patil ST, Zhang L, Martenyl F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomised Phase 2 clinical trial. Nat Med 2007; 13: 102-1107.
42. Harrison PJ. Metabotropic glutamate receptor agonists for schizophrenia. Brit J Psychiatry 2008; 192: 86-87.
43. Hecht EM and Landy DC. Alpha-2-receptor add-on therapy in the treatment of schizophrenia: a meta-analysis. Schizophr Res 2011; 134: 202-206.
44. Bymaster FP, Shannon HE, Rasmussen K, et al. Potential role of muscarinic receptors in schizophrenia. Life Sci 1999; 64: 527-534.
45. Henquet C, Sewell A, Kuepper R, et al. The acute effects of cannabinoids in patients with schizophrenia. In: Castle D, Murray RM, D'Souza CD (eds) Marijuana and madness. 2nd ed. Cambridge: Cambridge University Press, 2012; 198-209.